Picture of OptiNose logo

OPTN — OptiNose News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

OptiNose Inc expected to post a loss of 8 cents a share - Earnings Preview

* OptiNose Inc  OPTN.OQ   OPTN.O  is expected to show a rise
in
quarterly revenue when it reports  results on August 8 for the
period ending June 30 2024
    * The Yardley Pennsylvania-based  company is expected to
report a
5.8% increase in revenue to $20.582 million from $19.45 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for OptiNose Inc is for a
loss
of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for OptiNose
Inc is
$3.00​, above​ its last closing price of $0.99. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.11       -0.11      -0.12     Missed  -11.6
 Jan. 1 0001   -0.09       -0.09      -0.09     Met     4.6
 Sep. 30 2023  -0.09       -0.09      -0.08     Beat    15.2​
 Jun. 30 2023  -0.11       -0.11      0.02      Beat    118.4
 ​​Jan.        -0.14       -0.14      -0.17     Missed  -22
 1 0001                                                 
 Dec. 31 2022  -0.17       -0.17      -0.17     Met     2.7​
 Sep. 30 2022  -0.17       -0.18      -0.18     Met     2.7
 Jun. 30 2022  -0.24       -0.24      -0.23     Beat    4.2
 This summary was machine generated August 6 at 18:55 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on OptiNose

See all news